Serial No. US 5.057,546 Inventor Charlotte A. KENS. For SAPONIN ADJUVANT	L, et al. Filed AUGUST 27, 1990
() Affidavit/Declaration () Amendment () Response () Application pages () claims drawing sheets () Assignment () Cover Sheet () Brief (in triplicate) () Declaration & Power of Attorney () Executed () Unexecuted () Copy () Declaration of Inventor(s) () Executed () Unexecuted () Copy () Design Application () Disclaimer () Disclaimer Fee () Disclosure Statement () Form PTO-1449 () w/refs. () w/o refs. () Drawings, Formal Sheets Figures Other: AND EXCLUSION OF	() Fee Address Indication Form () Fee Calculation () Issue Fee Transmittal () Notice of Appeal () Oral Hearing Request/Confirm () Petition to Extend Time month(s) () Petition under 37 C.F.R Power of Attorney by Assignee () Associate with Revocation () Request for Correction of Filing Receipt () Sequence Listing w/Computer Readable and Paper Copy () Small Entity Statement () Status Letter () Transmittal Letter
File No. 8449-159	Sender: AMA /AWC

Express Mail No.: EL 477 034 050 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Charlotte A. Kensil, et al.

Serial No.: 07/573,268 Patent No.: 5,057,540

Filed: August 27, 1990 Issued: October 15 1991

For: SAPONIN ADJUVANT Attorney Docket No.: 8449-159

REVOCATION AND POWER OF ATTORNEY BY ASSIGNEE AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71

Commissioner for Patents Washington, D.C. 20231

SIR:

Antigenics, Inc., a Massachusetts corporation, having an address at 34 Commerce Way, Woburn, Massachusetts 01801, certifies that it is the owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified patent application by virtue of a chain of title from the inventors of the above-identified patent application to the current assignee as shown below:

- (1) an assignment recorded on August 4, 1988, at Reel 4925, Frame 0862, from the inventor(s) to Cambridge Biotech Corporation;
- (2) an assignment recorded on December 12, 1996, at Reel 8268, Frame 0033, from Cambridge Biotech Corporation to Aquila Biopharmaceuticals, Inc.; and
- (3) a change of assignee from Aquila Biopharmaceuticals, Inc. to
 Antigenics, Inc. by virtue of a merger, established by copies of merger
 documents submitted herewith.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Antigenics, Inc., assignee and owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified application hereby revokes all previous powers of attorney and appoints: Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), Thomas E. Friebel (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), Alan Tenenbaum (Reg. No. 34939), Michael J. Lyons (Reg. No. 37386), Garland T. Stephens (Reg. No. 37242), William J. Sipio (Reg. No. 34514), Nikolaos C. George (Reg. No. 39201), Stephen S. Rabinowitz (Reg. No. 40286), Ognjan V. Shentov (Reg. No. 38051), and Kenneth L. Stein (Reg. No. 38704), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006, and 3300 Hillview Avenue, Palo Alto, California 94304, and each of them its attorneys, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71, provided that, if any one of these attorneys ceases being affiliated with the law firm of Pennie & Edmonds LLP as partner, counsel, or employee, then the appointment of that attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all future correspondence to Pennie & Edmonds LLP, located at 1155 Avenue of the Americas, New York, New York 10036-2711, and direct all telephone calls to Pennie & Edmonds LLP at (212) 790-9090.

Signature:	Rusey Hanh	
Typed Name:	Russell Herndon	
Position/Title:	Chief Operating Officer	
Address:	34 Commerce Way	
	Woburn, Massachusetts 01801	
Date:	1/17/02	